New Oral Anticoagulant and Cancer Drug Believed to Be Firsts

By McCann, Jean | Drug Topics, January 3, 2000 | Go to article overview

New Oral Anticoagulant and Cancer Drug Believed to Be Firsts


McCann, Jean, Drug Topics


Favorable clinical trial reports on three unusual drugs aroused considerable interest at the annual meeting of the American Society of Hematology held in New Orleans recently. Still investigational at present, they are:

*the first oral anticoagulant (H376/ 95, AstraZeneca) to be introduced in 50 years

*an oral inhibitor(ST1 571, Novartis) that knocks down the high white blood cell counts of patients with leukemia who are refractory to interferon therapy *the once-banned thalidomide, which has been making a successful comeback (Thalomid, Celgene Corp.). Some 25 reports at this meeting addressed its successful application in chronic myelogenous leukemia and other hematologic diseases. According to the manufacturer, a pivotal trial for thalidomide for multiple myeloma is being considered for approval by the Food & Drug Administration.

As for the new oral anticoagulant, it has several unique aspects. Its mechanism of action is different from that of all other anticoagulants in that it acts as a direct thrombin inhibitor only. Also, it is convenient as an oral drug. So indicated its lead investigator, Bengt Eriksson, M.D., who is associate professor of orthopaedic surgery at the Sahlgrenska University Hospital in Gothenburg, Sweden. However, he added, the drug also comes in an injectable formulation for times when a patient can't swallow a pill, such as just prior to surgery

Another advantage Eriksson sees is that patients on H376/95 do not require coagulation monitoring. The therapeutic window, he noted, is far wider than that for either heparin or warfarin. In addition, he found no interactions with food or with other drugs.

In safety and efficacy studies in 300 patients undergoing total hip or knee replacement, Eriksson found the side effects to be similar to those in patients receiving a low molecular weight heparin. The pooled incidence of proximal deep vein thrombosis was 3% for the prodrug and 7% for the low molecular weight heparin, dalteparin (Fragmin, Pharmacia & Upjohn).

Eriksson added that the number of people needing a drug like this to prevent deep vein thrombosis following orthopedic joint surgery is already about a million a year in the United States and Europe--and that number, with the aging of the population, is certain to increase, he said.

The aging of the population is also likely to create a rising demand for Novartis' new drug, which inhibits the tyrosine kinase of the Bcr/ABLfusion oncoprotein, created by chromosomal translocation--the exchange of chromosomes 9 and 22.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

New Oral Anticoagulant and Cancer Drug Believed to Be Firsts
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.